Fruquintinib or Regorafenib? A Weighted Toxicity Score Analysis to Facilitate Better Discussions on Toxicity and Benefits in Later-line Colorectal Cancer Treatment
Fruquintinib or Regorafenib? A Weighted Toxicity Score Analysis to Facilitate Better Discussions on Toxicity and Benefits in Later-line Colorectal Cancer Treatment. // Clinical Colorectal Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1533002826000289?dgcid=rss_sd_all
Fruquintinib or Regorafenib? A Weighted Toxicity Score Analysis to Facilitate Better Discussions on Toxicity and Benefits in Later-line Colorectal Cancer Treatment. Clinical Colorectal Cancer. https://www.sciencedirect.com/science/article/pii/S1533002826000289?dgcid=rss_sd_all
“Fruquintinib or Regorafenib? A Weighted Toxicity Score Analysis to Facilitate Better Discussions on Toxicity and Benefits in Later-line Colorectal Cancer Treatment.” Clinical Colorectal Cancer.
@article{article40587,
title = {Fruquintinib or Regorafenib? A Weighted Toxicity Score Analysis to Facilitate Better Discussions on Toxicity and Benefits in Later-line Colorectal Cancer Treatment},
journal = {Clinical Colorectal Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1533002826000289?dgcid=rss_sd_all}
}